SuperworthAlpha Teknova TKNO
- Market cap
- $344.7M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 7.9×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $43.7M
- +12% on a year ago
- Net margin
- −38.4%
- Free cash flow yield
- −2.1%
Alpha Teknova trades at 7.9× sales. Its trailing earnings are negative, so it has no PE. Revenue was $43.7M over the last twelve months, up 12% on a year earlier with a −38% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $8.2M−24% | $7.9M−0% | $9.3M+2% | $9.6M−17% | $9.6M+17% | $9.3M+18% | $9.8M+5% | $10.3M+7% | $10.5M+9% | $10M+8% | $11.1M+13% | $12.2M+19% | |
| Cost of revenue | $6.7M+13% | $6.5M+13% | $7.1M+6% | $6.8M+5% | $9.5M+42% | $7.1M+9% | $6.8M−4% | $6.3M−7% | $7.2M−24% | $6.7M−6% | $7.3M+7% | $7.3M+16% |
| Gross profit | $1.5M−69% | $1.3M−37% | $2.2M−9% | $2.8M−45% | $90K−94% | $2.1M+59% | $3M+36% | $4M+42% | $3.2M+3462% | $3.2M+52% | $3.8M+26% | $4.9M+23% |
| R&D | $1.4M−27% | $1.3M−30% | $860K−38% | $678K−54% | $627K−55% | $594K−55% | $552K−36% | $581K−14% | $542K−14% | $522K−12% | $609K+10% | $554K−5% |
| SG&A | $8.6M−4% | $8.4M−16% | $9M−7% | $6.9M−15% | $6.6M−23% | $6.9M−18% | $7.1M−21% | $6.5M−6% | $6.4M−3% | $7M+3% | $7.2M+1% | $6.9M+7% |
| −$8.8M−62% | −$10.9M−24% | −$8M−11% | −$5.1M−27% | −$7.4M−15% | −$5.6M−48% | −$5M−38% | −$3.4M−34% | −$4M−46% | −$4.6M−18% | −$4.3M−13% | −$2.9M−15% | |
| Interest expense | $791K | −$173K | $145K | $272K−12% | $141K−82% | $129K | $144K−1% | $165K−39% | $190K+35% | $211K+64% | $219K+52% | $252K+53% |
| Pre-tax income | −$10.1M−56% | −$11M−22% | −$8.1M−8% | −$5.4M−25% | −$7.6M−25% | −$5.8M−48% | −$4.6M−43% | −$3.6M−34% | −$4.2M−44% | −$4.8M−16% | −$4.5M−3% | −$3.1M−12% |
| $9K | −$304K−62% | −$34K+89% | −$8K | −$8K | −$38K−88% | $22K | $19K | $79K | −$62K+63% | $47K+114% | $30K+58% | |
| Net income | −$10.2M−55% | −$10.7M−20% | −$8.1M−8% | −$5.4M−25% | −$7.6M−26% | −$5.7M−46% | −$4.6M−43% | −$3.6M−33% | −$4.3M−43% | −$4.8M−17% | −$4.6M−2% | −$3.2M−11% |
| −$0.34−58% | −$0.26−45% | −$0.20−36% | −$0.13−48% | −$0.15−56% | −$0.11−58% | −$0.09−55% | −$0.07−46% | −$0.08−47% | −$0.09−18% | −$0.08−11% | −$0.06−14% | |
| 30M+7% | 40.8M+45% | 40.8M+45% | 40.9M+45% | 51.8M+73% | 53.4M+31% | 53.4M+31% | 53.4M+31% | 53.5M+3% | 53.5M+0% | 53.6M+0% | 53.6M+0% |
Revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Cost of revenue: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Gross profit: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
R&D: Q1 FY20: 6 months less the 3 months printed beside them.
SG&A: Q1 FY20: 6 months less the 3 months printed beside them.
Operating income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY20: 6 months less the 3 months printed beside them.
Income tax: Q1 FY20: 6 months less the 3 months printed beside them.
Net income: Q1 FY20 and Q1 FY21: 6 months less the 3 months printed beside them.
EPS, diluted: 8 periods, Q1 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY20: share-days: the 6-month average less the second quarter's. Q4 FY20: share-days: the 12-month average less the 9-month, weighted by days. 5 periods, Q4 FY21 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Healthcare nearest Alpha Teknova's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| TKNOAlpha Teknova | $344.7M | n/m | n/a | 7.9× | +12% | −38.4% | |
| VMDViemed Healthcare | $373.3M | 27.2× | 26.1× | 1.2× | +25% | 4.8% | |
| EMBCEmbecta | $380.2M | 4.6× | 11.7× | 0.4× | −8% | 8.6% | |
| INFUInfuSystem | $277.6M | 34.0× | 43.5× | 1.9× | +2% | 6.0% | |
| ARVNArvinas | $477.3M | 45.6× | 52.3× | 1.5× | −15% | 2.9% | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| UTMDUtah Medical Products | $236.3M | 22.6× | 20.9× | 6.5× | −7% | 29.0% | |
| TCMDTactile Systems Technology | $535.5M | 21.9× | 62.9× | 1.5× | +17% | 7.1% | |
| ELMDElectromed | $220.6M | 20.1× | 29.0× | 3.0× | +15% | 15.3% | |
| SBCSBC Medical | $543M | 11.2× | 8.2× | 3.1× | −7% | 28.0% | |
| NATRNatures Sunshine Products | $213.8M | 12.0× | 20.6× | 0.4× | +7% | 3.7% | |
| Peer median | $376.7M | 22.3× | 27.6× | 1.7× | +1% | 6.5% |
More on Alpha Teknova
Each number over time
- PE ratio
- Price to sales ratio
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .